Loading...
XSHE
300254
Market cap345mUSD
Jul 10, Last price  
11.60CNY
1D
-1.54%
1Q
17.39%
Jan 2017
-46.81%
IPO
-14.60%
Name

Shanxi C&Y Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300254 chart
No data to show
P/E
111.24
P/S
3.51
EPS
0.10
Div Yield, %
Shrs. gr., 5y
3.03%
Rev. gr., 5y
-6.80%
Revenues
799m
-3.58%
203,666,798203,666,798243,618,734319,552,530310,780,744361,500,206513,510,739653,655,235683,934,855746,076,863938,927,9861,136,495,6671,131,801,411848,072,527930,374,948828,997,054799,305,103
Net income
25m
13,035,04413,035,04428,900,35647,983,62235,344,03525,801,04627,112,43940,997,49722,900,02930,147,70721,673,4197,241,0805,296,78800025,195,587
CFO
38m
-49.50%
0105,550,37552,032,4634,750,02235,051,20580,581,53382,191,77715,443,10841,650,14040,103,87838,440,74369,631,646096,921,05874,876,11637,814,367
Dividend
Jul 11, 20190.02 CNY/sh

Profile

ShanXi C&Y Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China, the United States, Hong Kong, and internationally. It offers products for pregnant women and babies; urinary system products; anti-infection products; traditional Chinese medicines; and dermatology products, as well as tea bags. The company was formerly known as Shanxi C&Y Pharmaceutical Co., Ltd. and changed its name to Shanxi C&Y Pharmaceutical Group Co., Ltd. in September 2014. Shanxi C&Y Pharmaceutical Group Co., LTD. was founded in 2005 and is headquartered in Shanghai, China.
IPO date
Aug 19, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
799,305
-3.58%
828,997
-10.90%
Cost of revenue
605,330
756,379
Unusual Expense (Income)
NOPBT
193,975
72,618
NOPBT Margin
24.27%
8.76%
Operating Taxes
6,553
7,970
Tax Rate
3.38%
10.98%
NOPAT
187,422
64,647
Net income
25,196
 
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
67,432
407,937
Long-term debt
177,670
216,493
Deferred revenue
8,607
8,867
Other long-term liabilities
17,399
10,124
Net debt
11,376
195,344
Cash flow
Cash from operating activities
37,814
74,876
CAPEX
(33,916)
Cash from investing activities
72,104
Cash from financing activities
(241,772)
112,564
FCF
298,658
101,242
Balance
Cash
132,004
263,946
Long term investments
101,723
165,141
Excess cash
193,761
387,636
Stockholders' equity
419,918
414,330
Invested Capital
836,893
940,679
ROIC
21.09%
6.60%
ROCE
17.99%
5.31%
EV
Common stock shares outstanding
241,619
237,069
Price
9.63
42.25%
6.77
-22.09%
Market cap
2,326,787
44.97%
1,604,959
-18.99%
EV
2,516,462
1,955,062
EBITDA
252,500
137,403
EV/EBITDA
9.97
14.23
Interest
33,293
46,063
Interest/NOPBT
17.16%
63.43%